Table 2.

Relation of OPG, RANKL, and RANKL/OPG Ratio With Clinicopathologic Parameters of Metastatic Female Breast Cancer Patients

Clinicopathologic Parameters	No.	OPG (Median)	p	RANKL (Median)	p	RANKL/OPG (Median)	p
Menopausal status			0.14		0.21		0.45
Pre	16 (36.4%)	57		15		0.43
Post	28 (63.6%)	62.6		17.22		0.36
Hypertension			0.076		0.63		0.094
Present	19 (43.2%)	101		15.25		0.17
Absent	25 (56.8%)	38.5		19		0.3793
Diabetes mellitus			0.006		0.47		0.005
Present	15 (34.1%)	106		15.25		0.16
Absent	29 (65.9%)	44.75		18.37		0.34
Grading			0.884		0.83		0.94
G1	11 (25%)	70		24		0.43
G2	22 (50%)	73.50		16.5		0.26
G3	11 (25%)	73.50		16.50		0.232
ER			0.124		0.54		0.19
Positive	31 (70.5%)	63.25		16.5		0.27
Negative	13 (29.5%)	101.50		15.87		0.16
PR			0.031		0.81		0.14
Positive	29 (65.9%)	62.75		16.5		0.27
Negative	15 (34.1%)	151		17.75		0.16
HER2 (2 cases missing)			0.890		0.52		0.49
Positive	16 (38.1%)	82		15.25		0.15
Negative	26 (61.9%)	73.50		17.75		0.25
Serum calcium			0.53		0.04		0.17
Increased	11 (25.0%)	69		20.6		0.17
Normal	33 (75.0%)	69		14.6		0.34
Subtypes of breast cancer (2 cases unknown)			0.18		0.25		0.23
Luminal A	5 (11.9%)	57		15.3		0.30
Luminal B	19 (45.2%)	75		22.1		0.25
Her2	12 (28.6%)	183		12.8		0.10
TNBC	6 (14.3%)	191		19		0.09
Previous aromatase inhibitors			0.019		0.11		0.12
Absent	34 (77.3%)	36		14		0.55
Present	10 (22.7%)	91.50		18.37		0.20
Previous tamoxifen			0.24		0.63		0.24
Absent	35 (79.5%)	68.15		18.4		0.22
Present	9 (20.5%)	93.45		14.67		0.20
Previous chemotherapy			0.17		0.91		0.35
Absent	34 (77.3%)	98.15		14.28		0.23
Present	10 (22.7%)	108.24		16.59		0.19